Flight Of The Navigator: Bluebird bio's Andrew Obenshain
The gene therapy firm is transitioning to a commercial organization
For 12 years, bluebird bio has been developing gene therapies for rare genetic disease and now, with two approvals under its belt, the company is continuing to explore uncharted territory as it brings forward innovative new treatments. Holding the map is CEO Andrew Obenshain.
